BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 21975290)

  • 21. Prevalence of extrapancreatic cancers in patients with histologically proven intraductal papillary mucinous neoplasms of the pancreas: a case-control study.
    Baumgaertner I; Corcos O; Couvelard A; Sauvanet A; Rebours V; Vullierme MP; Hentic O; Hammel P; Lévy P; Ruszniewski P
    Am J Gastroenterol; 2008 Nov; 103(11):2878-82. PubMed ID: 18853975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Invasive carcinoma originating in an intraductal papillary mucinous neoplasm of the pancreas: a clinicopathologic comparison with a common type of invasive ductal carcinoma.
    Shimada K; Sakamoto Y; Sano T; Kosuge T; Hiraoka N
    Pancreas; 2006 Apr; 32(3):281-7. PubMed ID: 16628084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
    Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE
    Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions.
    Lucas AL; Shakya R; Lipsyc MD; Mitchel EB; Kumar S; Hwang C; Deng L; Devoe C; Chabot JA; Szabolcs M; Ludwig T; Chung WK; Frucht H
    Clin Cancer Res; 2013 Jul; 19(13):3396-403. PubMed ID: 23658460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer.
    Campbell IG; Choong D; Chenevix-Trench G;
    Breast Cancer Res; 2004; 6(4):R366-71. PubMed ID: 15217503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer risk among the relatives of patients with pancreatic ductal adenocarcinoma.
    Del Chiaro M; Zerbi A; Falconi M; Bertacca L; Polese M; Sartori N; Boggi U; Casari G; Longoni BM; Salvia R; Caligo MA; Di Carlo V; Pederzoli P; Presciuttini S; Mosca F
    Pancreatology; 2007; 7(5-6):459-69. PubMed ID: 17912010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
    Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E
    Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRCA2 mutations as a universal risk factor for pancreatic cancer has a limited role in Korean ethnic group.
    Cho JH; Bang S; Park SW; Chung JB; Song SY
    Pancreas; 2008 May; 36(4):337-40. PubMed ID: 18437078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN.
    Yamaguchi K; Kanemitsu S; Hatori T; Maguchi H; Shimizu Y; Tada M; Nakagohri T; Hanada K; Osanai M; Noda Y; Nakaizumi A; Furukawa T; Ban S; Nobukawa B; Kato Y; Tanaka M
    Pancreas; 2011 May; 40(4):571-80. PubMed ID: 21499212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pancreatic juice cytology in the diagnosis of intraductal papillary mucinous neoplasm of the pancreas: significance of sampling by peroral pancreatoscopy.
    Yamaguchi T; Shirai Y; Ishihara T; Sudo K; Nakagawa A; Ito H; Miyazaki M; Nomura F; Saisho H
    Cancer; 2005 Dec; 104(12):2830-6. PubMed ID: 16287152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intraductal papillary mucinous neoplasm of the pancreas: cytologic features predict histologic grade.
    Michaels PJ; Brachtel EF; Bounds BC; Brugge WR; Pitman MB
    Cancer; 2006 Jun; 108(3):163-73. PubMed ID: 16550572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
    Lavie O; Hornreich G; Ben-Arie A; Rennert G; Cohen Y; Keidar R; Sagi S; Lahad EL; Auslander R; Beller U
    Gynecol Oncol; 2004 Feb; 92(2):521-4. PubMed ID: 14766242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.
    Lalloo F; Varley J; Moran A; Ellis D; O'dair L; Pharoah P; Antoniou A; Hartley R; Shenton A; Seal S; Bulman B; Howell A; Evans DG
    Eur J Cancer; 2006 May; 42(8):1143-50. PubMed ID: 16644204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
    Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
    Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence and risk factors of extrapancreatic malignancies in a large cohort of patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
    Larghi A; Panic N; Capurso G; Leoncini E; Arzani D; Salvia R; Del Chiaro M; Frulloni L; Arcidiacono PG; Zerbi A; Manta R; Fabbri C; Ventrucci M; Tarantino I; Piciucchi M; Carnuccio A; Boggi U; Costamagna G; Delle Fave G; Pezzilli R; Bassi C; Bulajic M; Ricciardi W; Boccia S
    Ann Oncol; 2013 Jul; 24(7):1907-1911. PubMed ID: 23676419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between pancreatic intraductal papillary mucinous neoplasms and extrapancreatic malignancies.
    Marchegiani G; Malleo G; D'Haese JG; Wenzel P; Keskin M; Pugliese L; Borin A; Benning V; Nilsson L; Oruc N; Segersvard R; Friess H; Schmid R; Löhr M; Maisonneuve P; Bassi C; Ceyhan GO; Salvia R; Del Chiaro M
    Clin Gastroenterol Hepatol; 2015 Jun; 13(6):1162-9. PubMed ID: 25478920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic testing by cancer site: pancreas.
    Axilbund JE; Wiley EA
    Cancer J; 2012; 18(4):350-4. PubMed ID: 22846737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients with deleterious germline mutations: A heterogeneous population for pancreatic cancer screening?
    Roch AM; Kim RC; Nguyen TK; House MG; Zyromski NJ; Nakeeb A; Schmidt CM; Ceppa EP
    J Surg Oncol; 2023 Aug; 128(2):289-294. PubMed ID: 37083062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short-term Results of a Magnetic Resonance Imaging-Based Swedish Screening Program for Individuals at Risk for Pancreatic Cancer.
    Del Chiaro M; Verbeke CS; Kartalis N; Pozzi Mucelli R; Gustafsson P; Hansson J; Haas SL; Segersvärd R; Andren-Sandberg Å; Löhr JM
    JAMA Surg; 2015 Jun; 150(6):512-8. PubMed ID: 25853369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PanGen-Fam: Spanish registry of hereditary pancreatic cancer.
    Mocci E; Guillen-Ponce C; Earl J; Marquez M; Solera J; Salazar-López MT; Calcedo-Arnáiz C; Vázquez-Sequeiros E; Montans J; Muñoz-Beltrán M; Vicente-Bártulos A; González-Gordaliza C; Sanjuanbenito A; Guerrero C; Mendía E; Lisa E; Lobo E; Martínez JC; Real FX; Malats N; Carrato A
    Eur J Cancer; 2015 Sep; 51(14):1911-7. PubMed ID: 26212471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.